Bacterial Infections  >>  Cayston (aztreonam lysine)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cayston (aztreonam lysine) / Gilead
NCT01059565 / 2009-011740-19: Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection

Completed
3b
102
US, Canada
AZLI, Placebo
Gilead Sciences
Cystic Fibrosis, Burkholderia Infections
09/11
01/12
AIR-CF4, NCT00712166 / 2015-000395-97: Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa

Completed
3
160
US, Canada, RoW
AZLI 75 mg three times daily (TID), Placebo three times daily (TID)
Gilead Sciences
Cystic Fibrosis, Lung Infection, Pseudomonas Aeruginosa
06/09
08/09
NCT01404234 / 2011-001362-18: Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways

Completed
3
61
US, Europe
AZLI, Cayston®
Gilead Sciences
Cystic Fibrosis, Pseudomonas Aeruginosa
04/13
04/13
AZLI CAT, NCT01641822 / 2015-000398-11: Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

Completed
3
107
US
AZLI, Cayston®, Placebo to match AZLI, Tobramycin inhalation solution, TOBI®
Gilead Sciences
Cystic Fibrosis
01/15
01/15

Download Options